• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2012 Product Image

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2012

  • Published: September 2012
  • 50 pages
  • Global Markets Direct

Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis). Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vaginal Atrophy (Atrophic Vaginitis).
- READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Vaginal Atrophy (Atrophic Vaginitis) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) 7
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics under Development by Companies 9
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics – Products under Development by Companies 14
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Vaginal Atrophy (Atrophic Vaginitis) Therapeutics Development 16
Bayer AG 16
Pear Tree Pharmaceuticals 17
Pantarhei Bioscience BV 18
Hygeia Therapeutics, Inc. 19
Vaginal Atrophy (Atrophic Vaginitis) – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
E-4 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
HYG-102 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
HYG-101 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
lasofoxifene tartrate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
tamoxifen citrate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
estradiol - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
estriol - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
prasterone - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
oxytocin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics – Drug Profile Updates 38
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics – Discontinued Products 39
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Dormant Products 40
Vaginal Atrophy (Atrophic Vaginitis) – Product Development Milestones 41
Featured News & Press Releases 41
Jan 05, 2012: Peptonic's Oxytocin Receives Approval For Dose-Finding Trial From Swedish Medical Products Agency 41
Nov 10, 2010: Hygeia Therapeutics Announces Successful Completion Of Preclinical Studies For HYG-102 41
May 12, 2010: Ospemifene May Be Safe, Effective for Vulvovaginal Atrophy 41
Mar 02, 2010: Shionogi Enters Into Exclusive License Agreement With Quatrx Pharmaceuticals To Market Ospemifene 42
Sep 10, 2009: Quatrx Announces Positive Results Of Second Pivotal Phase 3 Clinical Study For Ophena (Ospemifene Tablets) In Treatment Of Postmenopausal Vaginal Atrophy 43
Jul 29, 2009: Quatrx Announces Further Positive Phase 3 Results for ophena (ospemifene tablets) in postmenopausal vaginal atrophy 44
Mar 31, 2009: Quatrx Completes Erollment Of Ophena (ospemifene tablets) Final Pivotal Phase 3 Study In Women With Postmenopausal Vaginal Atrophy 45
Sep 26, 2008: Bionovo's VG101 Shows Greater Efficacy Than Estrogen In The Treatment Of Vaginal Dryness 46
Sep 24, 2008: Quatrx Pharmaceuticals Announces Additional Data From Phase 3 Study For Ophena (Ospemifene Tablets) Showing Improvements In Clinical Symptoms Of Vulvovaginal Atrophy 46
Sep 04, 2008: Quatrx Initiates Second Phase 3 Study Of Ophena (ospemifene tablets) In Women With Postmenopausal Vaginal Syndrome 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables
Number of Products Under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2012 7
Products under Development for Vaginal Atrophy (Atrophic Vaginitis) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Bayer AG, H2 2012 16
Pear Tree Pharmaceuticals, H2 2012 17
Pantarhei Bioscience BV, H2 2012 18
Hygeia Therapeutics, Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics – Drug Profile Updates 38
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics – Discontinued Products 39
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2012 7
Products under Development for Vaginal Atrophy (Atrophic Vaginitis) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos